MedTrace Logo

Effects of Vitamin B1 in Type 1 Diabetic Patients

NCT00117026 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2013-05-10

No results posted yet for this study

Summary

The purpose of this study is to determine whether benfotiamine supplementation can reduce markers of microvascular complications in type 1 diabetic patients.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

Placebo

Placebo for benfotiamine

DRUG

Benfotiamine

300mg/day

Sponsors & Collaborators

  • The Research Council of Norway

    collaborator OTHER

  • University Hospital, Aker

    lead OTHER

Principal Investigators

  • Kristian F Hanssen, MD, PhD · University Hospital, Aker

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2010-06-30
Completion
2011-02-28

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00117026 on ClinicalTrials.gov